

CURRICULUM VITAE

NAME: Allen L. Yeilding, M.D.

HOME ADDRESS: 2931 Canterbury Road
Birmingham, Alabama 35223
(205) 879-3334 – Home
(205) 901-1402 – Cell

WORK ADDRESS: 513 Brookwood Boulevard – Suite 275
Birmingham, AL 35209
(205) 502-4700 – Office
(205) 889-0135 – Pager

DATE OF BIRTH: February 10, 1956

PLACE OF BIRTH: Birmingham, Alabama

ALABAMA LICENSE: 10908

EDUCATION: B.S., Arts and Sciences - Cum Laude
University of Alabama
June - 1978

M.D.
University of Alabama at Birmingham
June - 1982

Internship and Residency - Internal Medicine
Carraway Methodist Medical Center
Birmingham, Alabama
July 1982 - June 1985

Fellowship - Hematology/Oncology
University of Alabama at Birmingham
Birmingham, Alabama
July 1985 - June 1988

PROFESSIONAL EXPERIENCE:

September 2002 – Present Hematology & Oncology Associates of Alabama, LLC
513 Brookwood Boulevard – Suite 275
Birmingham, AL 35209

 Hematology & Oncology Associates of Alabama, LLC
209 West Spring Street – Suite 303
Sylacauga, AL 35150

September 2001 – September 2002 US Oncology
Birmingham, AL

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

July 1988 – September 2001 Norwood Clinic
1528 Carraway Blvd.
Birmingham, AL 35234

Investigator, CALGB
Investigator, NSABP

CERTIFICATIONS:

National Boards (Part 1) - 1980
National Boards (Part 2) - 1982
National Boards (Part 3) – 1983

American Board of Internal Medicine
Diplomat - September 1985

American Board of Medical Oncology
Diplomat – 1987

American Board of Hematology
Diplomat - 1990

MEMBERSHIPS:

American Medical Association
Jefferson County Medical Association
American Society of Hematology
American Society of Clinical Oncology
Kiwanis Club of Birmingham
Board of Governors, Country Club of Birmingham 1993 - 2004
A Club, University of Alabama
The University Of Alabama President's Cabinet
The University Of Alabama Board Of Visitors Honor's College - 2004 to present
The University of Alabama Board of International Honors Program

HONORS

All SEC Golf Team - 1977
Jimmie Moore Memorial Trophy - 1977/1978
Phi Beta Kappa, University of Alabama
Tuscaloosa, Alabama - June 1978
Captain, Alabama Golf Team - 1978
Physician's Recognition Award – 1990
Alabama State Mid Amateur Champion - 1991
President, Alabama Society of Clinical Oncology 1991
President Birmingham Country Club - 2001
Best Docs - Birmingham Magazine – 2002 – 2011
Board of Directors-Brookwood Medical Center-2010- present
Vestry-St Mary's Church on the Highlands-2010-2013
Chairman, UA Board of Visitors Honor College 2011 - 2013
Board of Directors City Equity Theater 2011 - present

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

PUBLICATIONS

Csepreghy M, **Yeilding A**, Lilly M, Scott CW, Prchal JT: Characterization of a new glucose-6-phosphate dehydrogenase variant: G6PD-Central City. *Am J Hematol* 28:61-62, 1988.

Yeilding A, Jeffries B, Weppleman B, Prasthofer E: Extramedullary plasmacytoma associated with HIV infection. *American Journal of Medicine*, 1988 (Submitted).

Yeilding A, Bertoli L, Esenberg P, Plezia P, Modiano M, Alberts D, Khojasteh A, Gandara D, Cramer M, Shah A, Hahne W: Antiemetic efficacy of two different single intravenous doses of dolasetron during repeated courses of high-dose cisplatin-containing chemotherapy. *Am J Clin Oncol (CCT)* 19(6): 619-623, 1996.

Bertoli L, **Yeilding A**, Cramer M, Whitmore J, Hahne W: A double-blind, randomized, parallel, dosing-finding study of single-dose intravenous dolasetron mesylate in patients receiving high-dose (≥ 80 mg/m²) cisplatin-containing chemotherapy.

ABSTRACTS

Csepreghy M, **Yeilding A**: Characterization of two G6PD variants associated with hemolysis, G6PD-Central City and G6PD-Ensley.

Csepreghy M, **Yeilding A**: Apparent two G6PD variants in erythrocytes of an XY male.

Yeilding A: Glucose-6-phosphate dehydrogenase mRNA expression in G6PD-Alabama. A unique product of a single mutant gene yielding two proteins in reticulocytes.

PRESENTATIONS

1986 Trainee Research Symposium

Csepreghy M, **Yeilding A**: Characterization of two G6PD variants associated with hemolysis, G6PD-Central City and G6PD-Ensley.

Csepreghy M, **Yeilding A**: Apparent two G6PD variants in erythrocytes in an XY male.

1987 Trainee Research Symposium

Yeilding A: Variable mRNA expression among glucose-6-phosphate dehydrogenase variants.

Yeilding A: Glucose-6-phosphate dehydrogenase mRNA expression in G6PD-Alabama. A unique product of a single mutant gene yielding two proteins in reticulocytes.

CLINICAL TRIALS EXPERIENCE

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

Principal Investigator - "A double-blind, randomized parallel dose-finding study of single-dose intravenous MDL 73, 147EF in patients receiving high dose (>80mg/m²) Cisplatin-containing chemotherapy". Merrell Down Research Institute.

Principal Investigator - "Re-treatment protocol for the use of single-dose IV MDL 73, 147ER in patients receiving high dose (>80mg/m²) Cisplatin-containing chemotherapy". Merrell Down Research Institute.

Principal Investigator - "A double-blind, multicenter, parallel study comparing the efficacy and safety of oral Granisetron Hydrochloride 2mg with IV Ondansetrol Hydrochloride 32mg. Given once in the prevention of nausea and vomiting induced by IV Cyclophosphamide based or Carboplatin-based chemotherapy in patients with malignant disease". SmithKline Beecham.

Principal Investigator - "The effect of subcutaneous r-HuEPO in patients with small cell lung cancer (SCLC): A randomized, double-blind, placebo-controlled trial". R.W. Johnson.

Sub-Investigator - "Comparison of TLC D-99 Doxorubicin liposome injection versus Doxorubicin injection in metastatic breast cancer". Pfizer.

Principal Investigator - "A double-blind, randomized, parallel group study comparing the safety, efficacy, and quality of life of Opioid naive patients with cancer-related pain

treated with controlled-release Oxycodone (OxyContin) or immediate-released Oxycodone/APAP tablets". Purdue Pharma L.P.

Principal Investigator - "A multicenter labelling validation trial to assess the use of Kadian capsules in treating patients with moderate to severe pain". F.H. Faulding/New Drug Services.

Sub-Investigator - "Effectiveness of oral Dolesetron Mesylate (50mg) versus Prochlorperazine in the treatment of nausea and emesis due to fractionated abdominal radiotherapy". Hoechst Marion Roussel/A.R. Kamm.

Principal Investigator - "A randomized, double-blind, multicenter study of low-dose Gallium Nitrate for treatment of bone involvement due to multiple myeloma". SoloPak/New Drug Services.

Principal Investigator - "An open-label, controlled, randomized study to identify a single subcutaneous dose of procrit (Epoetin Alfa) that can be given weekly rather than the standard T.I.W. dose for the treatment of anemia in cancer subjects receiving platinum-containing chemotherapy". R.W. Johnson.

Principal Investigator - NSABP P-01: "A clinical trial to determine the worth of Tamoxifen for preventing breast cancer".

Principal Investigator - NSABP C-05: "A clinical trial to assess relative efficacy of 5-FU + Leucovorin with or without Interferon Alfa-2a in patient with Dukes' B and C carcinoma of the colon".

Principal Investigator - NSABP C-06: "A clinical trial comparing oral Uracil/Ftorafur (UFT) plus Leucovorin (LV) with %-Fluorouracil (5-FU) plus LV in the treatment of patients with Stages II and III carcinoma of the colon".

Principal Investigator - NSABP B-23: "A clinical trial comparing short, intensive AC +/- Tamoxifen with conventional CMF +/- Tamoxifen in node-negative breast cancer patients with ER-negative tumors".

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

Principal Investigator - NSABP B-28: "A randomized trial evaluating the worth of Paclitaxel (Taxol) following Doxorubicin (Adriamycin)/Cyclophosphamide in breast cancer patients with positive axillary nodes".

Principal Investigator - NSABP B-29: "A clinical trial to evaluate the benefit for adding Ocetrotide (SMS 201-995 PA LAR) to Tamoxifen alone or to Tamoxifen and chemotherapy in patients with axillary node-negative, estrogen-receptor-positive, primary invasive breast cancer".

Principal Investigator - CALGB 8361: "Diagnostic studies in AML".

Principal Investigator - CALGB 8461: "Cytogenetic studies in acute leukemia".

Principal Investigator - CALGB 8541: "Adjuvant CAF for pathologic Stage II, node + breast cancer: randomized among intensive CAF for four cycles vs. low dose CAF for four cycles vs. standard dose CAF for six cycles".

Principal Investigator - CALGB 8856: "CHOPE for advanced Hodgkin's disease: A Phase II study".

Principal Investigator - CALGB 8891: "Trial of cystectomy alone versus neoadjuvant M-VAC + cystectomy in patients with locally advanced bladder cancer".

Principal Investigator - CALGB 8896: "A prospectively randomized trial of low dose Leucovorin + 5-FU high dose Leucovorin + 5-FU, or low dose Leucovorin + 5-FU + Levamisole following curative resection in selected patients with Dukes' B or C colon cancer".

Principal Investigator - CALGB 8897: "Comparison of adjuvant chemotherapy with or without endocrine therapy in high-risk, node negative breast cancer patients and a natural history follow-up in low-risk node negative patients: an intergroup Phase III study".

Principal Investigator - CALGB 9051: "A Phase II study of Etoposide, Vinblastine, Doxorubicin (EVA) and subtotal nodal radiation in poor risk, early stage Hodgkin's disease".

Principal Investigator - CALGB 9191: "Phase III randomized study of ALL-trans retinoic acid versus Cytarabine Arabinoside and Daunorubicin as induction therapy for patients with previously untreated acute promyelocytic leukemia".

Principal Investigator - CALGB 9232: "Hematopoietic growth factor support versus prophylactic antibiotic support in advanced non-small cell lung cancer: a prospective double-blind randomized control trial: Phase III study".

Principal Investigator - CALGB 9235: "Etoposide, Cisplatin and radiation therapy with or without Tamoxifen in limited stage small cell lung cancer: a randomized Phase III study".

Principal Investigator - CALGB 9342: "Phase III study of Taxol at three dose levels in the treatment of patients with metastatic breast cancer".

Principal Investigator - CALGB 9344: "Doxorubicin dose escalation, with or without Taxol, as part of the CA adjuvant chemotherapy regimen for node positive breast cancer: A Phase III intergroup study".

Principal Investigator - CALGB 9351: "Phase II study of high dose CHOP in previously untreated low intermediate, high intermediate, and high risk non-Hodgkin's lymphoma: IWF grade E,F,G,H".

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

Principal Investigator - CALGB 9391: "Randomized trial of subtotal nodal irradiation versus Doxorubicin plus Vinblastine and subtotal nodal irradiation for Stage I-IIA Hodgkin's disease, Phase III".

Principal Investigator - CALGB 9393: "Prospective randomized trial of post-operative adjuvant therapy in patients with completely resected Stage II and Stage IIIA non-small cell lung cancer".

Principal Investigator - CALGB 9394: "Phase III comparison of adjuvant chemotherapy with high-dose Cyclophosphamide plus Doxorubicin (AC) versus sequential Doxorubicin followed by Cyclophosphamide (A--C) in high-risk breast cancer patients with 1-3 positive nodes".

Principal Investigator - CALGB 9395: "Phase III intergroup prospectively randomized trial of perioperative 5-FU after curative resection followed by 5-FU/Levamisole for patients with colon cancer".

Principal Investigator - CALGB 9484: "Linkage of molecular and epidemiological breast cancer investigations with treatment data: A specialized registry".

Principal Investigator - CALGB 9491: "Postoperative evaluation of 5-FU by bolus injection vs. 5-FU by prolonged venous infusion prior to and following combined prolonged venous infusion plus pelvic XRT plus bolus 5-FU plus Leucovorin in patients with rectal cancer".

Principal Investigator - CALGB 9493: "Treatment of pathologic Stage C carcinoma of the prostate with adjuvant radiotherapy".

Principal Investigator - CALGB 9497: "Health status and quality of life (QL) in patients with early stage Hodgkin's disease: A companion study of CALGB 9391/SWOG 9133".

Principal Investigator - CALGB 9621: "Phase I study of MDR modulation with PSC-833 (NSC #648265) with a pilot study of cytogenetic risk-adapted consolidation followed by a Phase II pilot study of immunotherapy with rIL-2 (NSC #373364) in previously untreated patients with ADL <60 years".

Principal Investigator - CALGB 9665: "The CALGB Leukemia Tissue Band".

Principal Investigator - Schering-Plough C97-042: "**Breast**-Comparison of the effect of SCH 57050 and Anastrozole in subjects with breast cancer relapsing after an initial response to Tamoxifen or showing progression after Tamoxifen given as adjuvant to surgery: a prospective double-blind Phase III trial".

Principal Investigator - Bristol B98-1280: "**Breast**-A phase III trial of Taxol7/Doxorubicin (two dose levels) versus Doxorubicin/Cytoxan7 followed by a comparison of weekly versus q3 weekly Taxol in patients with metastatic breast cancer".

Principal Investigator - Novartis 4244603010: "**Breast/Mx Myeloma**-A randomized, double-blind, multicenter, comparative trial of I.V. Zoledronate (4mg or 8mg) versus I.V. Aredia (90mg), as an adjuvant to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions".

Principal Investigator - Tax/Men.08: "**Lung**-Advanced non-small cell lung cancer after prior Platinum (Cisplatin or Carboplatin) based therapy utilizing weekly Taxol7 (Paclitaxel) versus observation followed by weekly Taxol7".

Principal Investigator - Ortho Biotech PR97-27-042: "**Anemia**-Clinica evaluation of once weekly dosing of Procrit in anemic cancer patients receiving chemotherapy".

Principal Investigator - R.W. Johnson N93-004: The effect of subcutaneous r-HuEPO in patients with small cell lung cancer (SCLC): A randomized, double-blind, placebo controlled trial.

Yeilding, Allen L.
Curriculum Vitae
Revised 03/31/2010

Principal Investigator - Bristol-Myers CA142-029: A double-blind, randomized Phase II study of oral Platinum JM-216 plus Prednisone or placebo plus Prednisone in patients with symptomatic hormone-refractory prostate cancer.

Principal Investigator - Schering-Plough C98-026: A Phase II/III trial of SCH 54031 (PEG Interferon alpha-2b/PEG Intron) vs Intron in subjects with newly diagnosed CML.

Principal Investigator - Schering-Plough C98-135: A randomized Phase II/III trial of SCH 54031 (PEG Interferon alpha-2b/PEG Intron) vs Intron as adjuvant therapy for malignant melanoma.

Principal Investigator - Pfizer 167-116-5188: Phase II multicenter, double-blind, randomized, placebo-controlled, multi-regimen study of CJ-11, 974 for the control of high dose Cisplatin chemotherapy-induced emesis.

Principal Investigator - Pfizer 167-117-5188: Phase II multicenter, double-blind, randomized, dose-ranging study of CJ-11, 974 for the control of Cyclophosphamide + Doxorubicin chemotherapy-induced emesis.

Principal Investigator - Glaxo Wellcome FUMA3008: A randomized open-label Phase III study of a 28-day oral regimen of 5-Fluorouracil plus 776C85 versus intravenous 5-Fluorouracil plus Leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.

Principal Investigator - Ortho McNeil CAPSS-078: Multicenter, randomized study to compare the safety and efficacy of oral Levofloxacin vs parenteral Ceftriaxone and Amikacin with the potential of conversion to oral Ciprofloxacin and Amoxicillin/Clavulanate in the treatment of subjects with Talcott Group IV febrile neutropenia.

Principal Investigator - R.W. Johnson LOFBIV-NEUT-001: Multicenter, double-blind, randomized study to compare the safety and efficacy of Levofloxacin with that of Cefepime in the treatment of fever and neutropenia.